HepaRegenix GmbH

https://www.heparegenix.com

Since 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). The first MKK4 inhibitor HRX-215 recently completed Phase 1 clinical testing. MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tuebingen, Germany. Investors in HepaRegeniX include Vesalius Biocapital IV, the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gru¨nderfonds (HTGF) and Ascenion GmbH. *

	Start	2016-02-05 established
	Industry	BIOTECH
	Industry 2	MKK4 inhibitor
	Person	Papatheodorou, Elias (HepaRegenix 202407– CEO before Genkyotex + Covagen + Medigene + Novosom + A.T.I. + Coca-Cola)
	Person 2	Albrecht, Wolfgang (HepaRegenix 201602– Managing Director)

	Region	Tübingen
	Country	Germany
	Street	63 Eisenbahnstr.
	City	72072 Tübingen
	Tel	+49-7071-7912810
		Address record changed: 2024-07-15

Basic data	Employees	n. a.

		* Document for »About Section«: HepaRegenix GmbH. (7/10/24). "Press Release: HepaRegeniX Raises €15 Million Series C Round to Advance Clinical Development of HRX-215 for Liver Regeneration". Tübingen.

		Record changed: 2024-07-15